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Conclusions. Losartan-sensitive renal damage caused byLosartan-sensitive renal damage caused by chronic NOS inhibi-
chronic NOS inhibition does not involve increased renal Angtion does not involve increased renal angiotensin II concentra-
II concentrations. This suggests that the detrimental effects oftions.
endogenous Ang II are increased during chronic NOS inhibi-Background. Chronic nitric oxide synthase (NOS) inhibition
tion. Thus, when NO levels are low, normal Ang II concentra-results in hypertension, proteinuria, and renal morphological
tions can cause renal injury and hypertension.changes. Continuous angiotensin II (Ang II) blockade prevents
these effects, suggesting an essential role of Ang II. However, it
is not known whether renal Ang II concentrations are primarily
increased or whether the scarcity of NO allows normal concen-
The endothelium plays an important role in the regula-trations of Ang II to cause these detrimental effects. Therefore,
tion of vascular tone and renal hemodynamics becausewe measured renal Ang II concentrations before and during
the development of renal damage. it can release a variety of vasoactive substances. The
Methods. Group 1 served as controls. Groups 2 through 5 importance of endothelium-derived nitric oxide (NO)
received the NOS inhibitor Nv-nitro-l-arginine (l-NNA; 40 can be derived from the observations that NO synthesismg/kg/day) for 4, 7, 14, and 21 days, respectively. Systolic blood
inhibition results in hypertension, renal vasoconstriction,pressure (SBP), proteinuria, glomerular filtration rate (GFR),
decreased glomerular filtration rate (GFR), proteinuria,and renal and blood Ang II were measured. In a separate
experiment, rats were treated with l-NNA 1 the Ang II AT1 and renal morphological changes such as thrombosis,
receptor blocker losartan to determine the functional effects glomerular collapse, and tubulointerstitial damage [1, 2].
of endogenous Ang II during chronic NOS inhibition. Several investigators have shown that during chronic NOResults. l-NNA treatment resulted in an increase in SBP
synthase (NOS) inhibition, continuous angiotensin IIfrom day 4 (161 6 4 vs. 135 6 4 mm Hg in control, P , 0.05)
(Ang II) blockade can prevent or blunt the hypertensiveto day 21 (230 6 9 mm Hg). GFR was decreased from day 4
(1.9 6 0.2 vs. 2.5 6 0.2 ml/min in control, P , 0.05) to day 21 [3–6] and renal functional and morphological conse-
(1.2 6 0.2 ml/min). Proteinuria was increased from day 14 quences [5, 6] of NOS inhibition. This preventive effect
(85 6 14 vs. 6 6 1 mg/day in control, P , 0.05) to day 21
indicates that Ang II plays an important role in the(226 6 30 mg/day). l-NNA treatment during four days resulted
pathogenesis of renal injury during chronic NOS inhibi-in a significant decrease in renal Ang II (183 6 32 vs. 454 6
40 fmol/g in control, P , 0.05). On day 7, 14, and 21, renal tion. This important role of Ang II does not seem to
Ang II was not significantly different from the control. Blood relate to circulating renin levels, which have been re-
Ang II was not significantly different from the control on days ported to be increased [5, 7], decreased [3, 8, 9], un-
4, 7, and 14 but was significantly increased after 21 days of
changed [4, 6], or variable [10] after chronic NOS inhibi-l-NNA treatment (215 6 35 vs. 78 6 13 fmol/ml in control,
tion.P , 0.05). Ang II type-1 (AT1) receptor blockade prevented
the severe renal injury and hypertension induced by chronic This apparent contradiction might be explained by
NOS inhibition. the possibility that the intrarenal renin-angiotensin (RA)
system dissociates from the plasma RA system. All of
the components of the RA system have been reportedKey words: nitric oxide synthase, hypertension, proteinuria, renal vaso-
constriction, renin-angiotensin system. to be present in the kidney, and it has been suggested
that intrarenal Ang II levels can be regulated indepen-Received for publication August 6, 1998
dently of the circulating RA system [11–13]. Such a disso-and in revised form January 25, 1999
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Ang II in the kidney, as well as the direct effects of NO placed in metabolism cages for 24 hours for determina-
tion of urinary protein and creatinine excretion. At theon renin release [14–16]. An alternative explanation is
that the decreased availability of NO after NOS inhibi- end of the experiment, the animals were anesthetized
intraperitoneally with 60 mg/kg sodium pentobarbital,tion leaves the activity of the RA system unbalanced,
resulting in an increased sensitivity to the detrimental and the femoral artery was cannulated to collect blood
samples for the determination of plasma creatinine con-effects of Ang II. This means that Ang II can have severe
detrimental effects, even without an elevation of Ang II centration.
Urinary protein levels were determined by the Brad-concentrations [9, 17].
The first aim of this study was to get more insight into ford method [18]. Plasma and urinary creatinine levels
were determined colorimetrically (Sigma). The creati-the Ang II dependence of the effects of chronic NOS
inhibition by measuring renal Ang II concentrations be- nine clearance, calculated by standard formula, was used
as an estimate of GFR.fore and during the development of renal damage. To
make this feasible, we used an accelerated model of NOS Angiotensin II measurements in kidney and blood. A
clamp was placed on the left renal artery, and a 2 mlinhibition, with a high dose of the potent NOS inhibitor,
Nv-nitro-l-arginine (l-NNA). We anticipated two possi- blood sample was collected from the femoral artery into
10 ml 95% prechilled methanol. The left kidney wasble outcomes. The first option was that the renal concen-
tration of Ang II was increased before the onset of renal rapidly excised, weighed, and homogenized in 10 ml 95%
prechilled methanol. Blood and kidney homogenatesdamage. The second option was that renal Ang II con-
centrations did not change before and during the initial were centrifuged immediately for 10 minutes at 2500
r.p.m. at 48C, and the supernatants were stored at 2208C.development of renal injury, indicating that the Ang II
dependence was caused by the scarcity of NO allowing Blood and renal Ang II were extracted and determined
by radioimmunoassay (RIA) according to the procedurenormal concentrations of Ang II to cause detrimental
effects. The second aim of this study was to determine of Fox et al [19]. On the day preceding the RIA, the
homogenates were evaporated to dryness under nitrogenthe functional effects of endogenous Ang II in this rapid
and severe model of chronic NOS inhibition. and redissolved in 1 ml assay buffer [0.1 m Tris containing
0.5% bovine serum albumin (BSA) and 0.1% lysozyme,
pH 7.4]. The samples were applied to phenyl-bonded
METHODS
solid phase extraction columns (Bond-Elut; Analy-
Animals tichem, Harbor City, CA, USA), which had been pre-
washed with 3 ml high-performance liquid chromatogra-Male Sprague-Dawley rats (180 to 210 g; Harlan-Olac,
Blackthorn, Bicester, Oxon, UK) received a standard phy (HPLC)-grade methanol and 3 ml ultrapure water.
After the application, the columns were washed sequen-natural diet (RMH-TM; Hope Farms, Woerden, The
Netherlands) containing 100 mmol/kg sodium and had tially with 3 ml H2O, 1 ml hexane, and 1 ml chloroform,
and Ang II was eluted with 2 3 1 ml 90% HPLC-gradefree access to tap water. They were exposed to a 12-
hour light/dark cycle, an ambient temperature of 228C methanol in ultrapure water. The combined elutes were
evaporated, and the residues were dissolved in 1 ml ofand humidity of 60%. Sentinel animals, which were
monitored regularly for infection by nematodes and assay buffer. Aliquots of these extracts and standard
Ang II (Peninsula, Belmont, CA, USA) were incubatedpathogenic bacteria, as well as antibodies to a large num-
ber of rodent viral pathogens (ICLAS, Nijmegen, The for 48 hours at 48C with 125I-labeled Ang II (Amersham,
Arlington Heights, IL, USA) and rabbit anti-Ang II anti-Netherlands) consistently tested negative for infection
throughout the course of the experiment. The protocol serum (Arnel, New York, NY, USA). Cross-reactions
of the antibody against Ang I and C-terminal Ang IIwas approved by the Utrecht University Board for stud-
ies in experimental animals. fragments were less than 1% and less than 0.1%, respec-
tively, except for Ang III, which exhibited a binding
Protocol 1 potency similar to that of Ang II. Bound and free Ang
II were separated by a second antibody precipitationFive groups of rats were studied (each N 5 9). The
first group received normal chow and water (control). with Sac-Cel (I.D.S., Washington, UK). The pellets were
counted in a Cobra Autogamma counter (Packard In-Groups 2, 3, 4, and 5 received the NOS inhibitor l-NNA
(Sigma Chemical Co., St. Louis, MO, USA) dissolved in struments, Warrenville, IL, USA), and concentrations
were calculated using logit-log transformation. The re-drinking water (500 mg/liter) for 4, 7, 14, and 21 days,
respectively. covery of Ang II added prior to extraction (40 fmol)
amounted to 67% for blood and 84% for kidneys. TheBlood pressure and renal function. At the end of the
different treatment periods, systolic blood pressure sensitivity of the assay was 0.5 fmol per assay tube. Blank
values were subtracted from the amounts of Ang II as-(SBP) was measured in the awake rats by the tail-cuff
method (IITC, San Diego, CA, USA). The rats were sayed in the samples. Unspecific binding of radiolabeled
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Ang II in the RIA was 2% or less, and the initial binding and water intake were measured weekly and were used
to calculate l-NNA and losartan intake.was 30 to 35%.
Blood pressure and renal function. Systolic blood
Morphological studies pressure and urinary protein excretion were measured
weekly starting one week before the start of the diet. AtThe right kidney was removed and processed for his-
tology. Kidneys were cut into 1 mm slices perpendicular the end of the experiment, urinary creatinine excretion
was also measured. The animals were weighed and anes-to the long axis, immersed in phosphate-buffered saline
(PBS) formaldehyde (4%, pH 7.35; PBS: 99 mm thetized intraperitoneally with 60 mg/kg of sodium pen-
tobarbital. The femoral artery was cannulated to collectNaH2PO4 3 H2O, 108 mm Na2HPO4 3 2H2O, and 248
mm NaCl), and embedded in paraffin. Light microscopy blood for the determination of plasma creatinine concen-
tration. Kidneys were processed for histology as de-was done in a blinded fashion on 3 mm sections of the
formaldehyde-fixed tissue that had been stained by peri- scribed in protocol 1.
odic acid-Schiff.
Statistical methodsVessels. Preglomerular vessels with endothelial dam-
age, thrombus, necrosis, and vasculitis were assessed as Results are expressed as mean 6 sem for quantitative
data and median and range for semiquantitative data.showing either a mild, moderate, or severe degree of
injury, and were evaluated in both the cortex and the Quantitative data were tested by one-way analysis of
variance (ANOVA) in protocol 1 and by two-wayouter medulla. The degree-specific vascular injury was
defined as the number of vessels with the respective (ANOVA) for repeated measures in protocol 2. Semi-
quantitative data were tested by the Kruskal–Wallisdegree of injury encountered in a whole kidney section,
divided by the total number of vessels in a whole kidney analysis of variance. If the variance ratio (F) reached
statistical significance (P , 0.05), quantitative data weresection and multiplied by 100. The total vascular injury
index was taken as the sum of all vessels with all degrees further analyzed with the Student–Newman–Keuls test
for multiple comparisons and semiquantitative data withof vascular injury, whereby the number of vessels with
degree 1 was multiplied by 1, that with degree 2 by 2, Dunn’s test for multiple comparisons.
and that with degree 3 by 3, divided by the total number
of vessels in a whole kidney section, and multiplied by
RESULTS
100 [20].
Protocol 1Glomeruli. One hundred glomeruli were evaluated.
The glomerular lesions that were observed were ischemia Blood pressure and renal function. l-NNA treatment
resulted in a significant increase in SBP from day 4 (161 6and the presence of protein droplets in glomerular vis-
ceral epithelial cells. The percentage of affected glomer- 4 vs. 135 6 4 mm Hg in control, P , 0.05) to day 21
(230 6 9 mm Hg; Fig. 1A). GFR was significantly de-uli was calculated.
Tubulointerstitium. Tubulointerstitial damage was qual- creased from day 4 (1.9 6 0.2 vs. 2.5 6 0.2 ml/min in
control, P , 0.05) to day 21 (1.2 6 0.2 ml/min; Fig. 1B).itatively assessed in the cortex and outer medulla as
mild, moderate, or severe, depending on the presence Proteinuria was significantly increased from day 14 (85 6
14 vs. 6 6 1 mg/day in control, P , 0.05) to day 21of infiltrated mononuclear cells and tubular damage in
20 microscopic fields with a magnification 3100, and an (226 6 30 mg/day; Fig. 1C).
Ang II measurements in kidney and blood. l-NNAaverage score per rat was calculated.
treatment during four days resulted in a significant de-
Protocol 2 crease in renal Ang II (183 6 32 vs. 454 6 40 fmol/g in
control, P , 0.05; Fig. 1D). On days 7, 14, and 21, renalFour groups of rats were studied. The control group
(N 5 8) received normal chow and water. The second Ang II was not significantly different from the control.
Blood Ang II was not significantly different from controlgroup (N 5 9) received l-NNA dissolved in drinking
water (500 mg/liter), the same dose as in protocol 1, on day 4, 7, and 14, but was significantly increased after
21 days of l-NNA treatment (215 6 35 vs. 78 6 13during 21 days. The third group (N 5 6) received the
Ang II type-1 (AT1) receptor antagonist losartan mixed fmol/ml in control, P , 0.05; Fig. 1E).
Morphological studies. After four days of l-NNAwith finely ground chow (400 mg/kg chow) during 21
days. The fourth group (N 5 8) received l-NNA dis- treatment, there were no significant renal morphological
changes, although very slight vascular injury was ob-solved in drinking water (500 mg/liter) and the Ang II
AT1 receptor antagonist losartan mixed with finely served that was characterized by focal adhesion of mono-
nuclear cells to the intima of the renal arteries (Fig. 2A).ground chow (400 mg/kg chow) during 21 days. Losartan
was kindly provided by R.D. Smith (DuPont-Merck Some tubulointerstitial damage was observed that was
characterized by an influx of mononuclear cells intoPharmaceuticals, Wilmington, DE, USA).
l-NNA and losartan intake. Body weight and food the interstitium, although the tubulointerstitial damage
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Fig. 1. Systolic blood pressure (A), glomerular filtration rate (B), pro-
teinuria (C), renal Ang II (D), and blood Ang II (E) in control rats
and rats treated with Nv-nitro-L-arginine (L-NNA) during 4, 7, 14, and
21 days. *P , 0.05 vs. control (day 0).
score was not significantly different from control (Table tubulointerstitial damage was mild (Table 1). After 14
days of treatment with l-NNA, vascular injury was char-1). After seven days of l-NNA treatment, there was mild
vascular injury in arteries as well as arterioles (Fig. 2B). acterized by pronounced focal adhesion and infiltration
of mononuclear cells into the intima and media of preglo-Some of the glomeruli (4.5%) showed ischemic retrac-
tion and solidification of the capillary convolute, and merular arteries and arterioles, which was sometimes
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Table 1. Renal vascular injury, glomerular ischemia and protein droplets and tubulointerstitial damage in control rats and in rats treated
with l-NNA during 4, 7, 14 and 21 days
Days
0 4 7 14 21
Vessels
Vascular injury
% Mild 0 3.3 17.3a 26.2b 26.5b
(0–3.6) (0.8–24.8) (4.2–22.2) (9.6–33.0) (19.5–42.2)
% Moderate 0 0 3.4 6.4a 9.4b
(0–0) (0–1.0) (0–4.2) (0–9) (4.9–14.8)
% Severe 0 0 0 1.2 11.3b
(0–0) (0–0) (0–0) (0–3.3) (2.4–22.4)
Total vascular injury index 0 3.6 21.2a 42.7b 90.7b
(0–3.6) (1–27) (4.2–30.6) (9.6–54) (37–111.8)
Glomeruli
With ischemic signs % 0 1 4.5b 6.5b 11.5b
(0–0) (0–3) (1–12) (4–8) (4–19)
With protein droplets % 1 1 2 11b 13b
(0–4) (0–4) (0–24) (3–16) (6–21)
Tubulointerstitium
Tubulointerstitial damage score 0 0.2 0.7a 1.4b 1.6b
(0–0.1) (0.1–0.4) (0.2–1.4) (1.2–1.6) (1.3–2.4)
Data are median (range).
a P , 0.05, b P , 0.01 vs. control
associated with a partial or total obstruction of the lumen control from seven days of treatment onward (Table 2).
The treatment of rats with losartan alone resulted in awith thrombotic material and/or necrosis (Fig. 2C). Some
slight increase in food intake during the first seven daysof the glomeruli (6.5%) showed ischemic changes, and
of treatment, whereas water intake was not different11% of the glomeruli showed protein droplets in visceral
from control. This resulted in a slightly higher losartanepithelial cells (Table 1). Tubulointerstitial damage was
intake in rats treated with losartan alone than in ratscharacterized by tubular atrophy and vacuolization and
treated with l-NNA 1 losartan during the first seveninterstitial mononuclear infiltration. After 21 days of
treatment with l-NNA, there was a further increase in
the severity of vascular injury, which was accompanied
by a significant increase in the percentage of glomeruli
c
with ischemic changes (Table 1 and Fig. 2D). Fig. 2. Representative light microscopic features of renal morphologi-
cal changes after 4, 7, 14, and 21 days of treatment with L-NNA. (A)
After four days of treatment with l-NNA, only very slight vascular,Protocol 2
specifically endothelial injury, was observed, with sticking of some mo-
l-NNA and losartan intake. Treatment of rats with nonuclear cells to endothelial cells. (B) After seven days of treatment
with l-NNA, mild to moderate vascular injury with pronounced mono-l-NNA dissolved in drinking water (500 mg/liter) re-
nuclear cell sticking to the endothelium, and infiltration of intima andsulted in an increase in water intake after 14 days of media could be observed; the periadventitial space was also moderately
treatment when compared with control, whereas food infiltrated by mononuclear cells. (C) After 14 days of l-NNA treatment,
moderate vascular injury with sticking of mononuclear cells to promi-intake was not different from control. This resulted in
nent vacuolated endothelial cells that were partly necrotic was observed;an increase in l-NNA intake from 41 6 3 mg/kg/day also, some vascular smooth muscle cells near the adventitia were ne-
crotic and surrounded by mononuclear cells. (D) After 21 days ofafter 7 days to 82 6 7 mg/kg/day after 21 days of treat-
treatment with l-NNA, focal chronic tubular interstitial damage withment (Table 2). To test whether this increase in water
collapse of tubular lumina, irregular vacuolation of tubular epithelia,
intake was secondary to the concentration defects caused and some infiltration of the interstitium by mononuclear cells could be
seen. The glomerulus shows slight ischemic damage with condensationby renal morphological changes, urine osmolality was
of mesangium and collapse of some capillaries (period acid-Schiff stain).measured. After 21 days of treatment with l-NNA, urine
Publication of this figure in color was made possible by a grant from
osmolality was 689 6 78 vs. 1658 6 130 mOsm/kg in Merck Sharpe & Dohme BV, Haarlem, The Netherlands.
control. This decrease in urine osmolality was probably
Fig. 4. Representative light microscopic feature of renal morphologysecondary to renal damage and not a primary effect of
after 21 days of combined administration of L-NNA 1 losartan. NoNOS inhibition on water intake, because water intake renal morphological changes were observed. The figure shows a regular
was not increased and urine osmolality was not de- glomerulus with typical mesangium and an arteriole with an increase
in renin producing cells (bright red intracellular droplets). The intersti-creased (1625 6 216 mOsm/kg) in the l-NNA group
tium is not edematous; proximal and distal tubules are regular (periodicafter seven days. Treatment of rats with l-NNA resulted acid-Schiff stain). Publication of this figure in color was made possible
by a grant from Merck Sharp & Dohme BV, Haarlem, The Netherlands.in a progressive decrease in growth when compared with
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Table 2. Body weight, food and water intake of control rats 3A) and proteinuria (22 6 4 mg/day; Fig. 3B) and the
and rats treated with l-NNA, losartan and l-NNA 1 losartan
decrease in GFR (2.18 6 0.27 ml/min), although SBPduring 21 days, as well as losartan and l-NNA intake
in the appropriate groups was significantly higher than SBP in rats treated with
losartan alone (P , 0.05).Days
Morphological studies. Renal morphological changes
0 7 14 21
after 21 days with l-NNA treatment corresponded with
Body weight g renal morphological changes as described in protocol 1.
Control 18863 22564 25065 27264
Treatment with l-NNA in combination with losartanl-NNA 19164 21064a 22564a 22866a
Losartan 20563a 25263a 27565a 29465 completely prevented vascular injury, glomerular ische-
l-NNA 1 losartan 18764b 22264b 23367b 245611b mia, and protein droplets and tubulointerstitial damage
Water intake ml/kg/day
[total vascular injury index: 0 (range, 0 to 2.4); percentageControl 87610 7968 6367 6068
l-NNA 7566 8165 10766a 165613a of glomeruli with ischemia, 0 (0 to 1); percentage of
Losartan 8064 7266 7365 7165 glomeruli with protein droplets, 0 (0 to 3); tubulointersti-
l-NNA 1 losartan 88616 75613 82618 91613c
tial damage score, 0.6 (0 to 1.5); Fig. 4]. Rats treated withFood intake g/kg/day
Control n.d. 6762 7662 6163 losartan alone showed no renal morphological changes.
l-NNA n.d. 7565 7766 7365 Renin droplets in afferent arterioles were frequently ob-
Losartan n.d. 9361a 7862 7561
served in rats treated with losartan (Fig. 4).l-NNA 1 losartan n.d. 7263b 8564 7263
l-NNA intake mg/kg/day
l-NNA — 4163 5463 8267
l-NNA 1 losartan — 3866 4169 4666c DISCUSSION
Losartan intake mg/kg/day
Our main finding was that plasma and renal Ang IILosartan — 3761 3161 3061
l-NNA 1 losartan — 2061b 3462 2961 concentrations were not increased during chronic NOS
Data are mean 6 sem. inhibition before the occurrence of hypertension and
a P , 0.05 vs control renal injury. In fact, the initial response was a decreaseb P , 0.05 vs. losartan
c P , 0.05 vs. l-NNA in renal Ang II. Nevertheless, Ang II AT1 receptor block-
ade completely prevented the severe renal injury and
hypertension induced by chronic NOS inhibition. These
findings strongly suggest that during chronic NOS inhibi-
days. After 14 and 21 days of treatment, losartan intake tion, even normal concentrations of Ang II exert detri-
mental effects.was approximately 30 mg/kg/day in rats treated with
It has been suggested that NO is a physiological antag-losartan alone and in rats treated with l-NNA 1 losartan
onist of the renal actions of Ang II [21]. NO and Ang(Table 2). Treatment of rats with l-NNA 1 losartan
II have a critical role in modulating afferent arteriolarresulted in an intake of l-NNA that was not different
vasomotor tone [22], tubuloglomerular feedback [23],from l-NNA intake in rats treated with l-NNA alone
and pressure natriuresis [24]. Consequently, the decreaseuntil 14 days of treatment (Table 2). After 21 days of
in renal Ang II by 60% after four days of NOS inhibitiontreatment, the intake of l-NNA in rats treated with
reflects the installation of a new equilibrium of vasodilat-l-NNA 1 losartan was significantly lower than in rats
ing and constricting substances and can be regarded astreated with l-NNA alone because no increase in water
an appropriate response to the increase in blood pressureintake was observed in rats treated with l-NNA 1 losar-
and renal perfusion pressure [25] after NOS inhibition.tan (Table 2).
The only component of the RA system that has beenBlood pressure and renal function. l-NNA treatment
extensively studied after NOS inhibition is renin. Indeed,
during 21 days resulted in an increase in SBP from day
most of the in vivo experiments in humans and various
7 to day 21 (Fig. 3A) and an increase in proteinuria from animal species [26–29] and experiments in isolated per-
day 14 to day 21 (Fig. 3B) in a pattern similar to that in fused kidneys [14–16] show that inhibitors of NOS reduce
protocol 1. After 21 days, GFR was significantly de- renal renin secretion [30]. The mechanisms underlying
creased (1.28 6 0.15 vs. 2.52 6 0.22 ml/min in control, this phenomenon remain to be resolved, but there is
P , 0.05). Treatment with losartan resulted in a decrease evidence that suppression of renin formation during
in SBP after seven days of treatment of 10 mm Hg (127 6 NOS inhibition is due to increased calcium entry into
3 mm Hg on day 7 vs. 137 6 4 mm Hg on day 0), although the renin-producing cells [31]. Another possibility is that
SBP was not significantly different from the control. The stimulation by NO is related to the cAMP pathway, and
treatment with losartan alone had no effect on protein- cGMP-induced inhibition of cAMP-phosphodiesterase
uria (27.0 6 3.0 mg/day) and GFR (2.00 6 0.05 ml/ III may mediate this effect [30]. Thus, a decrease in renal
min). Treatment with l-NNA 1 losartan during 21 days renin secretion may have preceded the decrease in renal
Ang II after four days of NOS inhibition.prevented the increase in SBP (159 6 7 mm Hg; Fig.
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Fig. 3. (A) Systolic blood pressure in control rats (squares) and rats treated for 21 days with L-NNA (circles), losartan (diamonds), or L-NNA 1
losartan (triangles). *P , 0.05 vs. control; #P , 0.05 vs. losartan. (B) Proteinuria in control rats (triangles) and rats treated for 21 days with
l-NNA (circles), losartan (diamonds), or l-NNA 1 losartan (triangles). *P , 0.05 vs. control.
This decrease in renal renin secretion after NOS inhi- After four days of NOS inhibition, there were no signifi-
cant renal morphological changes, whereas after sevenbition is not always accompanied by a decrease in plasma
renin activity (PRA) because increased [5, 7], decreased days of NOS inhibition, there was significant vascular
injury, glomerular ischemia, and tubulointerstitial dam-[3, 8, 9], or unchanged [4, 6] PRA was reported after
chronic NOS inhibition. Such a dissociation between kid- age. There was a progressive increase in severity of vas-
cular injury. After 14 and 21 days of NOS inhibition,ney and plasma was also observed in this study. While
renal Ang II was significantly decreased after four days partial or total obstruction of the vascular lumen with
thrombotic material was observed. This was accompa-of NOS inhibition, blood Ang II remained unchanged
at this time point. The reason for this divergence has nied by an increase in the number of ischemic glomeruli.
It has been shown that ischemic glomeruli may releasenot been investigated; however, there are several possi-
bilities. First, the vascular wall has a fully functional RA excessive amounts of renin [35], which in turn may have
increased renal Ang II. The combination of the inhibi-system [32]. Although the major source for vascular renin
is renal renin taken up by the arterial wall from the tory signals discussed earlier in this article, as well as the
stimulation of Ang II production by ischemia, probablycirculation, the vascular RA system may be able to main-
tain a normal level of vascular Ang II generation in the explains why the net effect after 21 days was a renal Ang
II concentration that was not different from the control.face of decreased renal renin [32]. For example, un-
changed vascular Ang II generation in models of low In addition, because only 12% of the glomeruli showed
ischemic changes after 21 days of NOS inhibition, it isrenin hypertension has been observed [33]. Second, an-
giotensin-degrading enzymes may be differently regu- probable that Ang II was supranormal in only certain
areas of the kidney, whereas elsewhere, the Ang II-low-lated in the kidney than in plasma or in the vascular
wall. After 7 and 14 days of NOS inhibition, plasma Ang ering effects of l-NNA still prevailed. Such a combina-
tion may have resulted in renal Ang II concentrationsII as well as renal Ang II were not different from control.
Garcia et al also found kidney tissue Ang II levels at after 21 days of NOS inhibition that were not higher
than control.control levels after 14 days of chronic NOS inhibition
[34]. Qiu et al have shown in a longitudinal study with The secondary increase in renal Ang II may have con-
tributed to the development of proteinuria by increasingcatheterized conscious rats that the PRA was highly vari-
able during chronic NOS inhibition [10]. Our finding— intraglomerular capillary pressure [36] and by decreasing
glomerular permselectivity [37]. Proteinuria, in turn, willthat plasma Ang II was initially unchanged but finally
increased—corroborates this variability. contribute to the development of tubulointerstitial injury
[38]. Ang II may also have contributed to the develop-The initial decrease in renal Ang II was not sustained.
After seven days of NOS inhibition, renal Ang II was ment of renal injury and hypertension via stimulation of
other factors such as oxygen radicals [39, 40], trans-significantly increased when compared with four days
of NOS inhibition, and renal Ang II was even further forming growth factor-b [41], or endothelin-1 [42, 43].
Indeed, we have shown in a previous study that blockadeincreased after 21 days of NOS inhibition. This increase
in renal Ang II paralleled the course of renal injury. of the endothelin A receptor during chronic NOS inhibi-
Verhagen et al: Chronic NOS inhibition and renal Ang II230
tion with l-NNA in the same dose as used in this study is caused by low levels of NO, this hypertension is Ang II
dependent, even though Ang II levels are not increased.completely prevented proteinuria and partly prevented
hypertension and renal morphological changes [44]. In conclusion, our finding of effective protection
against renal injury during chronic NOS inhibition byHowever, in this study, the treatment with l-NNA 1
losartan completely prevented hypertension and renal Ang II AT1 receptor blockade, despite unaltered or even
down-regulated renal Ang II levels, indicates that duringmorphological changes. This suggests that Ang II is the
main driving force in the cascade of events that results chronic NOS inhibition, the sensitivity to the detrimental
effects of endogenous Ang II is increased. Thus, whenin hypertension, proteinuria, and renal morphological
changes after chronic NOS inhibition and that, among there is insufficient NO, normal Ang II levels can cause
renal injury and hypertension.others, endothelin is also involved in this cascade.
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